Investigating how DNA changes affect the progression of HPV-related cervical lesions
The effect of epigenetic DNA methylation on the progression of HPV-associated precancerous cervical lesions
This study is looking at how changes in DNA can help us understand which women with early-stage cervical lesions caused by HPV might develop more serious issues, so we can better predict their risk and improve their care.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10771928 on NIH RePORTER |
What this research studies
This research focuses on understanding how changes in DNA methylation, a type of epigenetic alteration, influence the progression of precancerous cervical lesions associated with HPV infection. By analyzing the methylation patterns in patients with low-grade cervical intraepithelial neoplasia (CIN-1), the study aims to identify which cases are likely to progress to more severe forms of cervical disease. The research will utilize longitudinal clinical data to track these changes over time, potentially leading to better predictive markers for cervical cancer risk. Patients may be involved in providing samples and data to help elucidate these relationships.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with low-grade cervical intraepithelial neoplasia (CIN-1) who are being monitored for potential progression.
Not a fit: Patients with high-grade cervical lesions (CIN-2/3) or invasive cervical cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved methods for predicting which precancerous cervical lesions are likely to progress, allowing for more personalized and timely interventions.
How similar studies have performed: While there is some existing research on DNA methylation in cervical cancer, this specific approach focusing on the progression of CIN-1 lesions is relatively novel and underexplored.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Bukowski, Alexandra — Univ of North Carolina Chapel Hill
- Study coordinator: Bukowski, Alexandra
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.